ClinicalTrials.gg
RecruitingNCT05773989Updated Jan 26, 2024

Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy

A Phase 4 interventional study of CYP2C19 genotype guided P2Y12 monotherapy and Clopidogrel in Coronary Artery Disease and Platelet Reactivity, sponsored by St. Antonius Hospital. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-26.

Sponsored by St. Antonius Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies testing ticagrelor in Coronary Artery Disease — 5 open to participants now, 5 under way, 2 of them phase 3. Ticagrelor · Coronary Artery Disease.

Planned enrollment
34th of 78
88 · median 80
Started
2024
with 2 others
Phase 4
46 of 78
3 open now
Registered
75th of 78
by date

Among the 78 studies testing ticagrelor in Coronary Artery Disease, this one is the 34th largest by planned enrollment, is one of 3 that started in 2024, is one of 46 in phase 4, and was the 75th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 78 studies testing ticagrelor in Coronary Artery Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing ticagrelor in Coronary Artery Disease, or all of them as a file.
02

Study summary

Patients with Chronic Coronary Syndrome (CCS) undergoing with elective percutaneous coronary intervention (PCI) are treated with dual antiplatelet therapy (DAPT), consisting of aspirin combined with clopidogrel for 6 months. The aim of DAPT is to prevent recurrent thrombotic events, i.e. death, stent thrombosis and/ or myocardial infarction (MI). However, the trade-off of thrombotic prevention by DAPT is an increased risk of bleeding.

Multiple strategies to reduce bleeding risk and optimize outcomes have been proposed. On one hand the bleeding risk can be reduced by shortening the duration of DAPT and omitting aspirin. This has been proven effective in patients with acute coronary syndromes (ACS) compared to standard DAPT, without a significant difference in thrombotic events. On the other hand, personalized medicine by means of genotyping to ensure that a patient is treated with an, for them, effective drug, can be a strategy to optimize patients outcomes. In CCS patients the preferred P2Y12-inhibitor is clopidogrel. However, clopidogrel must first be activated by the CYP2C19 enzyme in the liver. Only then can clopidogrel inhibit the P2Y12-receptor and prevent platelet activation. Almost thirty percent of patients has a genetic variation of the gene encoding this CYP2C19 enzyme. In these patients, clopidogrel is not or hardly activated, putting them at a higher risk of thrombotic events than patients who do not have this gene variation. By determining the CYP2C19 genotype, it is possible to estimate whether clopidogrel will be effective or not.

In this trial the investigators evaluate the pharmacodynamic effects of genotype guided P2Y12-inhibitor monotherapy in patients with CCS undergoing PCI. In the intervention arm the CYP2C19 genotype will be assessed using a point-of-care test device on the cardiology ward, which can be performed by (research) nurses. Patients with a CYP2C19 loss-of-function (LOF) allel will be treated with monotherapy ticagrelor or prasugrel. Patients who are non-carrier of a LOF allel will receive clopidogrel. The control arm will be treated with the current standard-of-care, which is DAPT, consisting of aspirin combined with clopidogrel for 6 months.

The main goals is to assess the antithrombotic effects of individualized P2Y12 monotherapy strategy versus clopidogrel plus aspirin in elective PCI patients.

Read the detailed description

Rationale: Novel antithrombotic strategies, such as genotype-guided P2Y12-inhibitor selection and P2Y12-inhibitor monotherapy, instead of routine dual antithrombotic therapy (DAPT), have recently been investigated in major randomized controlled trials. It is unclear whether these therapies can also be applied to all comer patients undergoing elective percutaneous coronary (PCI) with stenting.

Objective: The aim of this study is to evaluate the pharmacodynamic response of CYP2C19-genotype-guided monotherapy in patients undergoing elective PCI. Bleeding and ischemic outcomes will also be registered.

Study design: A prospective, single center, randomized controlled trial.

Study population: Patients undergoing elective PCI

Intervention: Randomized to genotype-guided monotherapy P2Y12 inhibition or standard DAPT.

After PCI, patients will be randomised between two groups. Intervention group: P2Y12-inhibitor monotherapy. Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.

Control group: Dual antiplatelet therapy (DAPT). Patients will receive clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.

Main study parameters/endpoints:

  • To evaluate the antithrombotic effects of ticagrelor/prasugrel or clopidogrel monotherapy versus clopidogrel plus aspirin in order to assess the feasibility and safety of individualized antithrombotic therapy after elective PCI based on CYP2C19-genotyping.

Secondary endpoints:

  • The primary (safety) bleeding endpoint is the incidence of minor, moderate or severe bleeding (Bleeding Academic Research Consortium 2, 3 and 5)
  • The primary efficacy endpoint is the incidence of cardiovascular mortality, myocardial infarction, stent thrombosis, and stroke)
  • Individual components and combinations of the primary and secondary end points
  • To evaluate the net clinical benefit (a composite of all-cause death, MI, stroke and major bleeding defined as BARC type 3 or 5 bleeding at 6 months)
  • To compare the number of patients in whom the antiplatelet drug is prematurely discontinued or switched to another drug in the CYP2C19 genotype guided antiplatelet treatment versus standard DAPT treatment
03

Conditions studied

  • Coronary Artery Disease
  • Platelet Reactivity

Keywords

  • Percutaneous Coronary Intervention
  • Antithrombotic therapy
  • CYP2C19
  • CYP2C19 guided treatment
  • Pharmacodynamics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years of age
  • Patients with CCS undergoing successful elective PCI
  • Patients with written as approved by the ethics committee

Exclusion criteria

Exclusion Criteria:

  • to aspirin, ticagrelor, prasugrel or clopidogrel
  • Under the age of 18 years
  • Planned cardiac valve surgery
  • Need for chronic oral anticoagulation
  • PCI when admitted for ACS
  • \< 1 year
  • Unable or unwilling to provide
  • Pregnancy
  • Suboptimal result of stenting as defined by the operator, preferably explained according the complex-PCI criteria
  • Treatment with a strong inhibitor or inducer
  • Treatment with a strong CYP2C19 inhibitor or inducer
  • History of definite stent thrombosis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Genotype guided P2Y12 monotherapy

    Patients will be tested for the CYP2C19 genotype. Patients without a loss-of-function (LOF) allele will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.

    Drug: CYP2C19 genotype guided P2Y12 monotherapy

  • Active comparator
    Standard DAPT

    Patients will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.

    Drug: Clopidogrel

Interventions

  • DrugTicagrelorStudies of TicagrelorTicagrelor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.

    Also known as: Ticagrelor, Prasugrel, Clopidogrel

  • Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.

    Also known as: Aspirin

06

What researchers measure

Primary outcomes

  1. Platelet reactivity

    Change in P2Y12 Reaction Units (PRU) measured using the VerifyNow

    Time frame: Baseline and 30 days after PCI

  2. High on-treatment platelet reactivity (HTPR)

    Number of participants with high on-treatment platelet reactivity (HTPR) defined by a PRU \>208

    Time frame: 30 days

Secondary outcomes

  1. Bleeding complications

    Number of participants with major or clinically relevant bleeding complications according to the Bleeding Academic Research Consortium Definition for Bleeding (BARC) classification.

    Time frame: 6 months

  2. Myocardial infarction

    Number of participants with myocardial infarction as defined by the 4th Universal Definition of Myocardial Infarction

    Time frame: 6 months

  3. Stroke

    Number of participants with stroke as defined by the Valve Academic Research Consortium (VARC) definitions

    Time frame: 6 months

  4. Stent thrombosis

    Number of participants with stent thrombosis as defined by the Academic Research Consortium (ARC)

    Time frame: 6 months

  5. All-cause death

    Number of participants with all-cause death as defined by the Academic Research Consortium (ARC)

    Time frame: 6 months

  6. Cardiovascular death

    Number of participants with cardiovascular death as defined by the Academic Research Consortium (ARC)

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2024, 10 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 10 months is below that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2023
First posted
Mar 17, 2023
StartActual
Jan 23, 2024
Primary completionEst.
Dec 1, 2024
CompletionEst.
May 1, 2025
Last update
Jan 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05773989
Lead sponsor
St. Antonius Hospital
Responsible party
Jurriën M. ten Berg, MD, PhD (Principal Investigator, St. Antonius Hospital) — Principal investigator
First posted
Mar 17, 2023
Start date
Jan 23, 2024
Primary completion
Dec 1, 2024 (estimated)
Completion
May 1, 2025 (estimated)
Last update
Jan 26, 2024

Study contacts

Wout van den Broek, MD
Contact
w.van.den.broek2@antoniusziekenhuis.nl
088 320 1337
Jurriën ten Berg, MD, PhD
principal investigator · St. Antonius Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion